Saturday, October 31, 2026

Ericsson Stock Bearish By 11% So Far On Friday

Ericsson Stock Bearish By 11% So Far On Friday

(VIANEWS) - Shares of Ericsson (NASDAQ: ERIC) dropped by a staggering 11.06% to $5.11 at 11:48 EST on Friday, after three consecutive sessions in a row of gains. NASDAQ is jumping 0.36% to $14,188.91, after four consecutive sessions in a row of gains. This seems, at the moment, a somewhat up trend trading session today.

Ericsson's last close was $5.74, 26.5% below its 52-week high of $7.81.

About Ericsson

Telefonaktiebolaget LM Ericsson (publ), together with its subsidiaries, provides communication infrastructure, services, and software solutions to the telecom and other sectors. It operates through four segments: Networks, Cloud Software and Services, Enterprise, and Other. The Networks segment offers radio access network solutions for various network spectrum bands, including integrated high-performing hardware and software. This segment also provides active antenna and transport solutions; and a range of service portfolio covering network deployment and support. The Cloud Software and Services segment offers core networks, business and operational support systems, network design and optimization, and network managed services. The Enterprise segment offers global communications platform including cloud-based unified communications as a service, contact center as a service, and communications platform as a service; enterprise wireless solutions comprise private wireless networks and wireless wan pre-packaged solutions; and technologies and new business solutions, such as mobile financial services, security solutions, and advertising services. The Other segment includes Redbee media that prepares and distributes live and video services for broadcasters, sports leagues, and communications service providers. It operates in North America, Europe and Latin America, the Middle East and Africa, South East Asia, Oceania, India, North East Asia, and internationally. Telefonaktiebolaget LM Ericsson (publ) was founded in 1876 and is headquartered in Stockholm, Sweden.

Earnings Per Share

As for profitability, Ericsson has a trailing twelve months EPS of $0.48.

PE Ratio

Ericsson has a trailing twelve months price to earnings ratio of 10.64. Meaning, the purchaser of the share is investing $10.64 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.08%.

Moving Average

Ericsson's value is below its 50-day moving average of $5.27 and way below its 200-day moving average of $5.70.

Volume

Today's last reported volume for Ericsson is 12825122 which is 42.02% above its average volume of 9030230.

Sales Growth

Ericsson's sales growth is negative 3.4% for the present quarter and 0.5% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Ericsson's stock is considered to be oversold (<=20).

More news about Ericsson (ERIC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com